CAMBRIDGE, Mass., Aug. 26, 2025 -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced its participation in upcoming investor and industry conferences.
- September 3-5: Wells Fargo Healthcare Conference. Hyung Heon Kim, President and Chief Executive Officer will attend this conference in Boston, Massachusetts.
- September 8-10: H.C. Wainwright 27th Annual Global Investment Conference. Mr. Kim will participate in fireside chat. The Company's on-demand presentation will be available to view beginning Friday, September 5, 2025, at 7:00 am ET on the H.C. Wainwright Conference Portal and on the Event Calendar page of the MetaVia website https://ir.metaviatx.com/events-presentations/event-calendar.
Institutional investors who are registered for the conference can log into www.hcwevents.com to request a meeting with the company. - September 16-17: Obesity Science & Innovation 2025 Congress. Mr. Kim will present a company overview with a focus on DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that targets both the glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), for the treatment of obesity, at this conference in Boston, Massachusetts.
- October 7-9: Fierce Biotech Week. Mr. Kim will attend this conference in Boston, Massachusetts.
To schedule a meeting with management outside of these events, investors can contact Michael Miller at mmiller@rxir.com.
About MetaVia
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. In a Phase 1 multiple ascending dose (MAD) trial in obesity, DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist reduction. DA-1241 is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, DA-1241 demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control. In a Phase 2a clinical study, DA-1241 demonstrated direct hepatic action in addition to its glucose lowering effects.
For more information, please visit www.metaviatx.com.
Contacts:
MetaVia
Marshall H. Woodworth
Chief Financial Officer
+1-857-299-1033
marshall.woodworth@metaviatx.com
Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com
This News is brought to you by Qube Mark, your trusted source for the latest updates and insights in marketing technology. Stay tuned for more groundbreaking innovations in the world of technology.
